Logo] BENCHMARKFinancial Advisory Agreement • March 31st, 2023 • Cardio Diagnostics Holdings, Inc. • In vitro & in vivo diagnostic substances • New York
Contract Type FiledMarch 31st, 2023 Company Industry Jurisdiction
AMENDMENT NO. 1 ENGAGEMENT LETTEREngagement Letter • March 31st, 2023 • Cardio Diagnostics Holdings, Inc. • In vitro & in vivo diagnostic substances
Contract Type FiledMarch 31st, 2023 Company IndustryAmendment 1 dated November 14, 2022 (this “Amendment”) to the Engagement Letter dated as of May 13, 2022 between The Benchmark Company, LLC (“Benchmark”) and Cardio Diagnostics, Inc. [sic] (“Company”).